News Releases

ABOUT AINOS NEWS
搜尋新聞內容:
日期 標題
2021-11-03 Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development.
2021-08-16 Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives.
2021-06-14 Ainos Named Exclusive Sales Partner for COVID-19 Antigen Rapid Test Kit in Taiwan.
2021-05-24 Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to "AIMD", Engages Firm to Explore Listing Requirements of National Securities Exchanges
2021-04-21 Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
2020-12-30 Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth.
2020-09-10 Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board
2020-08-13 Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics.
2020-02-13 Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications.
2019-07-29 Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement
聯絡我們

美國:

8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108

 +1 (858) 869-2986


台灣:

新竹縣竹北市生醫五路66號10樓之2

 +886 (0)3-550-5199

 Email: info@ainos.com

關於我們

產品

AI 電子鼻

低劑量口服干擾素

合成 RNA

最新消息

隱私權政策

投資人關係

投資人關係首頁

股價資訊

投資者新聞

公司治理

財務資訊

電郵提示

代理商

INABATA & CO., LTD.

牛耳國際生技股份有限公司

社群

Linkedin

Twitter

FB

IG

Copyright © 2023 Ainos Inc. All rights reserved.